S&P 500   4,631.15 (+1.40%)
DOW   34,818.71 (+0.97%)
QQQ   398.68 (+1.23%)
AAPL   169.78 (+2.71%)
MSFT   337.83 (+2.19%)
FB   321.29 (-0.98%)
GOOGL   2,901.99 (+2.26%)
AMZN   3,531.53 (+0.70%)
TSLA   1,149.71 (+0.43%)
NVDA   329.22 (+0.75%)
BABA   125.57 (-1.54%)
NIO   40.14 (+2.58%)
CGC   10.43 (-2.61%)
AMD   157.27 (-0.69%)
GE   96.25 (+1.33%)
MU   88.53 (+5.39%)
T   22.69 (-0.61%)
F   20.25 (+5.52%)
DIS   145.91 (+0.70%)
PFE   54.47 (+1.38%)
ACB   6.31 (-1.71%)
AMC   33.72 (-0.65%)
BA   196.40 (-0.73%)
S&P 500   4,631.15 (+1.40%)
DOW   34,818.71 (+0.97%)
QQQ   398.68 (+1.23%)
AAPL   169.78 (+2.71%)
MSFT   337.83 (+2.19%)
FB   321.29 (-0.98%)
GOOGL   2,901.99 (+2.26%)
AMZN   3,531.53 (+0.70%)
TSLA   1,149.71 (+0.43%)
NVDA   329.22 (+0.75%)
BABA   125.57 (-1.54%)
NIO   40.14 (+2.58%)
CGC   10.43 (-2.61%)
AMD   157.27 (-0.69%)
GE   96.25 (+1.33%)
MU   88.53 (+5.39%)
T   22.69 (-0.61%)
F   20.25 (+5.52%)
DIS   145.91 (+0.70%)
PFE   54.47 (+1.38%)
ACB   6.31 (-1.71%)
AMC   33.72 (-0.65%)
BA   196.40 (-0.73%)
S&P 500   4,631.15 (+1.40%)
DOW   34,818.71 (+0.97%)
QQQ   398.68 (+1.23%)
AAPL   169.78 (+2.71%)
MSFT   337.83 (+2.19%)
FB   321.29 (-0.98%)
GOOGL   2,901.99 (+2.26%)
AMZN   3,531.53 (+0.70%)
TSLA   1,149.71 (+0.43%)
NVDA   329.22 (+0.75%)
BABA   125.57 (-1.54%)
NIO   40.14 (+2.58%)
CGC   10.43 (-2.61%)
AMD   157.27 (-0.69%)
GE   96.25 (+1.33%)
MU   88.53 (+5.39%)
T   22.69 (-0.61%)
F   20.25 (+5.52%)
DIS   145.91 (+0.70%)
PFE   54.47 (+1.38%)
ACB   6.31 (-1.71%)
AMC   33.72 (-0.65%)
BA   196.40 (-0.73%)
S&P 500   4,631.15 (+1.40%)
DOW   34,818.71 (+0.97%)
QQQ   398.68 (+1.23%)
AAPL   169.78 (+2.71%)
MSFT   337.83 (+2.19%)
FB   321.29 (-0.98%)
GOOGL   2,901.99 (+2.26%)
AMZN   3,531.53 (+0.70%)
TSLA   1,149.71 (+0.43%)
NVDA   329.22 (+0.75%)
BABA   125.57 (-1.54%)
NIO   40.14 (+2.58%)
CGC   10.43 (-2.61%)
AMD   157.27 (-0.69%)
GE   96.25 (+1.33%)
MU   88.53 (+5.39%)
T   22.69 (-0.61%)
F   20.25 (+5.52%)
DIS   145.91 (+0.70%)
PFE   54.47 (+1.38%)
ACB   6.31 (-1.71%)
AMC   33.72 (-0.65%)
BA   196.40 (-0.73%)
NASDAQ:AYLA

Ayala Pharmaceuticals Stock Forecast, Price & News

$10.14
+0.64 (+6.74%)
(As of 12/1/2021 11:00 AM ET)
Add
Compare
Today's Range
$10.14
$10.14
50-Day Range
$9.30
$14.09
52-Week Range
$7.74
$28.68
Volume
1 shs
Average Volume
28,550 shs
Market Capitalization
$141.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.26
30 days | 90 days | 365 days | Advanced Chart
Receive AYLA News and Ratings via Email

Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Ayala Pharmaceuticals logo

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.

Headlines

Ayala Pharmaceuticals Inc.
October 7, 2021 |  barrons.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AYLA
Fax
N/A
Employees
34
Year Founded
N/A

Sales & Book Value

Annual Sales
$3.71 million
Book Value
$3.00 per share

Profitability

Net Income
$-30.15 million
Net Margins
-1,177.26%
Pretax Margin
-1,158.62%

Debt

Price-To-Earnings

Miscellaneous

Free Float
13,531,000
Market Cap
$141.30 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/24/2022

MarketRank

Overall MarketRank

1.54 out of 5 stars

Medical Sector

1050th out of 1,392 stocks

Biological Products, Except Diagnostic Industry

161st out of 202 stocks

Analyst Opinion: 3.5Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Ayala Pharmaceuticals (NASDAQ:AYLA) Frequently Asked Questions

Is Ayala Pharmaceuticals a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ayala Pharmaceuticals stock.
View analyst ratings for Ayala Pharmaceuticals
or view top-rated stocks.

When is Ayala Pharmaceuticals' next earnings date?

Ayala Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Ayala Pharmaceuticals
.

How were Ayala Pharmaceuticals' earnings last quarter?

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) announced its quarterly earnings results on Monday, November, 15th. The company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($0.80) by $0.12. The business earned $0.63 million during the quarter, compared to the consensus estimate of $0.82 million. Ayala Pharmaceuticals had a negative trailing twelve-month return on equity of 91.26% and a negative net margin of 1,177.26%.
View Ayala Pharmaceuticals' earnings history
.

What price target have analysts set for AYLA?

5 equities research analysts have issued 12 month target prices for Ayala Pharmaceuticals' stock. Their forecasts range from $17.00 to $29.00. On average, they anticipate Ayala Pharmaceuticals' stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 136.7% from the stock's current price.
View analysts' price targets for Ayala Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Ayala Pharmaceuticals' key executives?

Ayala Pharmaceuticals' management team includes the following people:
  • Dr. Roni Mamluk, Pres, CEO & Director (Age 54, Pay $635.6k)
  • Mr. Yossi Maimon CPA, M.B.A., CPA, MBA, CFO, Sec. & Treasurer (Age 50, Pay $692.18k)
  • Dr. Gary B. Gordon M.D., Ph.D., Chief Medical Officer (Age 68, Pay $550.31k)

What other stocks do shareholders of Ayala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ayala Pharmaceuticals investors own include Moderna (MRNA), CrowdStrike (CRWD), Dynavax Technologies (DVAX), Square (SQ), Abbott Laboratories (ABT), Alpine Immune Sciences (ALPN), Advanced Micro Devices (AMD), BioLineRx (BLRX), Cognex (CGNX) and Micron Technology (MU).

When did Ayala Pharmaceuticals IPO?

(AYLA) raised $50 million in an initial public offering on Friday, May 8th 2020. The company issued 3,300,000 shares at $14.00-$16.50 per share. Citigroup and Jefferies served as the underwriters for the IPO and Oppenheimer and Raymond James were co-managers.

What is Ayala Pharmaceuticals' stock symbol?

Ayala Pharmaceuticals trades on the NASDAQ under the ticker symbol "AYLA."

Who are Ayala Pharmaceuticals' major shareholders?

Ayala Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (7.26%). Company insiders that own Ayala Pharmaceuticals stock include Gary B Gordon and Roni Mamluk.
View institutional ownership trends for Ayala Pharmaceuticals
.

Which major investors are buying Ayala Pharmaceuticals stock?

AYLA stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP.
View insider buying and selling activity for Ayala Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Ayala Pharmaceuticals?

Shares of AYLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ayala Pharmaceuticals' stock price today?

One share of AYLA stock can currently be purchased for approximately $10.14.

How much money does Ayala Pharmaceuticals make?

Ayala Pharmaceuticals has a market capitalization of $141.30 million and generates $3.71 million in revenue each year. The company earns $-30.15 million in net income (profit) each year or ($2.90) on an earnings per share basis.

How many employees does Ayala Pharmaceuticals have?

Ayala Pharmaceuticals employs 34 workers across the globe.

What is Ayala Pharmaceuticals' official website?

The official website for Ayala Pharmaceuticals is www.ayalapharma.com.

Where are Ayala Pharmaceuticals' headquarters?

Ayala Pharmaceuticals is headquartered at Oppenheimer 4, Rehovot L3, 7670104.

How can I contact Ayala Pharmaceuticals?

Ayala Pharmaceuticals' mailing address is Oppenheimer 4, Rehovot L3, 7670104. The company can be reached via phone at 857-444-0553 or via email at [email protected].


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.